Biotech Perspective

The Friday Biotech Perspective #41

A personal vaccine journey and … the Makary-Prasad-RFK Jr. guidance

Jun 2 •

The Friday Biotech Perspective #40

After the Whiplash

Apr 27 •

The Friday Biotech Perspective #39

Washington uncertainty, Trump tariffs dismantle global drug development

Apr 7 •

The Friday Biotech Perspective #38

Strong clinical performances still rise in Trump II bear market

Mar 16 •

The Friday Biotech Perspective #37

The Cost of Washington Chaos

Feb 8 •

The Friday Biotech Perspective #36

Inari, Intra-Cellular lead M&A first strikes in 2025

Jan 17 •

The Friday Biotech Perspective #35

A Championship Season for catalysts in 2024

Dec 31, 2024 •

The Friday Biotech Perspective #34

Summit Thera turns to China to reach the Summit … again

Dec 6, 2024 •

The Friday Biotech Perspective #33

Kura (KURA) secures major partnership … and stock declines?

Nov 23, 2024 •

The Friday Biotech Perspective #32

Were Coya’s mixed Alzheimer’s trial results a speedbump or partly by design?

Nov 8, 2024 •

The Friday Biotech Perspective #31

About All that Jazz

Oct 19, 2024 •

The Friday Biotech Perspective #30

The curious case of Eidos

Oct 4, 2024 •

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts